What You Should Know:
– Brixton Biosciences, a clinical-stage life sciences company focused on innovative pain treatments raises $33M in Series B funding led by Schooner Capital with participation from SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures.
– In addition, Brixton has bolstered its leadership team. Dr. Michael Fishman, a renowned pain management specialist, joins as Chief Medical Officer. Additionally, Reggie Groves, a seasoned industry veteran with experience at Medtronic, strengthens the company’s Board of Directors.
Brixton Biosciences: Pioneering Patient-Centric Pain Solutions
Founded by Massachusetts General Brigham, Brixton Biosciences is a clinical-stage leader in pain therapeutics. Their team boasts experienced management and esteemed medical advisors, united in a patient-centric vision. Leveraging in-depth research, Brixton addresses critical unmet needs in pain management, offering a promising alternative to traditional systemic medications. With its innovative Neural Ice™ platform, Brixton Biosciences is poised to transform pain management by offering safe, effective, and long-lasting drug-free relief.
Freeze Pain with Neural Ice
Brixton’s cutting-edge Neural Ice™ platform offers a compelling alternative. This innovative therapy directly targets nerves, potentially providing 3-6 months of pain relief through a simple, targeted, and familiar injectable approach. This funding round follows the exciting news of Neural Ice™ (formerly Coolio™ Therapy) receiving Breakthrough Device Designation from the FDA, highlighting its potential to revolutionize pain management.
Targeting Pivotal Trials and Platform Expansion
The new capital empowers Brixton to launch two crucial pivotal clinical studies. These studies will evaluate the efficacy and safety of their Neural Ice™ platform in treating knee pain associated with osteoarthritis and knee replacement surgery. Success in these trials paves the way for broader application of Neural Ice™ beyond the knee, targeting a wider range of pain conditions with a single, long-acting, injectable drug-free nerve block.
“We are delighted to welcome our new investors, led by Schooner Capital, as well as all of our existing investors, on our journey to bring to market products that disrupt the way we have traditionally come to think of pain treatment,” said Sameer Sabir, Chief Executive Officer of Brixton Biosciences. “As we use the proceeds of this funding to enter into regulatory clinical studies, our goal is to deliver a simple injectable nerve block that lasts for several months, rather than a day or so.”
